南京诺唯赞生物科技股份有限公司 2025年年度业绩预告

Core Viewpoint - The company, Nanjing Novogene Biotechnology Co., Ltd., anticipates a net loss for the fiscal year 2025, primarily due to increased VAT rates on biological products and rising sales expenses [2][5]. Group 1: Performance Forecast - The company expects a net profit attributable to shareholders of the parent company to be between -20 million and -10 million yuan for 2025 [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between -85 million and -70 million yuan [2]. - The financial data in this forecast has not been audited by registered accountants [2]. Group 2: Previous Year Performance - In the same period last year, the total profit was -58.25 million yuan, with a net profit attributable to shareholders of the parent company at -18.09 million yuan [3]. - The net profit after deducting non-recurring gains and losses was -83.22 million yuan [3]. - The earnings per share for the previous year were -0.05 yuan per share [4]. Group 3: Reasons for Performance Changes - The expected loss in 2025 is attributed to the VAT increase from 3% to 13%, adversely affecting overall revenue and profitability [5]. - The company is focusing on enhancing technology and product R&D, optimizing cost reduction and efficiency measures, while maintaining strong market investment and expanding innovative and overseas markets, which has led to increased sales expenses [5]. - The company has made provisions for credit impairment losses and asset impairment losses based on actual circumstances and prudence, which has also negatively impacted the current operating results [5].